New Survey Finds U.S. Biotechs Advancing Treatments for Rare and Serious Diseases ...

A survey of 37 U.S. biotech companies found that while most prefer conducting first-in-human clinical trials in the U.S., FDA regulatory hurdles including delays and financial costs are driving many to run trials overseas in Australia, Europe, and China instead.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.